Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lauren Dorosh"'
Autor:
Jason D. Katz, François G. Gervais, Lauren Dorosh, Milenko Cicmil, Khamir Mehta, Joey L. Methot, Janice D Woodhouse, Hongshi Yu, Hani Houshyar, Prasanthi Geda, Gretchen A. Baltus, Malgorzata A Gil, Antonio Cabal, Sanjiv J. Shah, Robbie L. McLeod, Dapeng Chen, Alan S. Bass, Stephen E. Alves, Michael Caniga
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 369:223-233
We leveraged a clinical pharmacokinetic (PK)/pharmacodynamics (PD)/efficacy relationship established with an oral phosphatidylinositol 3-kinase (PI3K)δ inhibitor (Idelalisib) in a nasal allergen challenge study to determine whether a comparable PK/P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ae30672ed16800c8692f183b1d4851d
https://doi.org/10.1124/jpet.118.252551
https://doi.org/10.1124/jpet.118.252551
Autor:
Kevin W. Johnson, Peter Fuller, Sujal V. Deshmukh, Fang He, Peter Goldenblatt, Lauren Dorosh, Hongbo Zeng, Jason D. Brubaker, Luis E. Torres, Tony Siu, Fiona Elwood, Charles A. Lesburg, Sangita B. Patel, Duan Liu, Elma Kadic, Christopher J. Dinsmore, Xavier Fradera, Lynsey Shaffer, Jonathan R. Young, Lily Y. Moy, Feng Shi, Carla Alpert, Joel A. Klappenbach, Joshua Close, Rafael Fernandez, Hongshi Yu, Nathan Bays, Dawn M. Mampreian
Publikováno v:
Journal of Medicinal Chemistry. 60:9676-9690
The discovery of a potent selective low dose Janus kinase 1 (JAK1) inhibitor suitable for clinical evaluation is described. As part of an overall goal to minimize dose, we pursued a medicinal chemistry strategy focused on optimization of key paramete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6959a9f84f358dff1679660f1f0b87e
https://doi.org/10.1021/acs.jmedchem.7b01135
https://doi.org/10.1021/acs.jmedchem.7b01135
Autor:
Robbie L, McLeod, Malgorzata A, Gil, Dapeng, Chen, Antonio, Cabal, Jason, Katz, Joey, Methot, Janice D, Woodhouse, Lauren, Dorosh, Prasanthi, Geda, Khamir, Mehta, Milenko, Cicmil, Gretchen A, Baltus, Alan, Bass, Hani, Houshyar, Michael, Caniga, Hongshi, Yu, Francois, Gervais, Stephen, Alves, Sanjiv, Shah
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 369(2)
We leveraged a clinical pharmacokinetic (PK)/pharmacodynamics (PD)/efficacy relationship established with an oral phosphatidylinositol 3-kinase (PI3K)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a514c7e08b5e85828f6fd96b70fba955
https://pubmed.ncbi.nlm.nih.gov/30804001
https://pubmed.ncbi.nlm.nih.gov/30804001
Autor:
Peter J. Dandliker, Hao Tang, Christopher J. Dinsmore, Chi-Sung Chiu, Fiona Elwood, Deborah Slipetz, Jennifer Piesvaux, Sujal V. Deshmukh, Ilona Kariv, Bo-Sheng Pan, Carla Alpert, Nathan Bays, Alan Byford, Alexey Rivkin, Peter Goldenblatt, Irena Ivanovska, Mark E. Scott, Joel A. Klappenbach, Hyun-Hee Lee, David J. Witter, Kalyan Chakravarthy, Lauren Dorosh, Yujie Qu, Brian Kraybill, Mark Zielstorff
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 361(2)
Reversible janus associated kinase (JAK) inhibitors such as tofacitinib and decernotinib block cytokine signaling and are efficacious in treating autoimmune diseases. However, therapeutic doses are limited due to inhibition of other JAK/signal transd
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30dcce0e8183db5060a7c6ebeec57fe3
https://pubmed.ncbi.nlm.nih.gov/28193636
https://pubmed.ncbi.nlm.nih.gov/28193636